Ignite Creation Date:
2025-12-24 @ 9:24 PM
Ignite Modification Date:
2026-02-22 @ 9:39 AM
Study NCT ID:
NCT02957032
Status:
TERMINATED
Last Update Posted:
2023-10-10
First Post:
2016-10-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor:
Philogen S.p.A.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-04-13
Start Date Type:
ACTUAL
Primary Completion Date:
2023-09-29
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-09-29
Completion Date Type:
ACTUAL
First Submit Date:
2016-10-17
First Submit QC Date:
None
Study First Post Date:
2016-11-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-06
Last Update Post Date:
2023-10-10
Last Update Post Date Type:
ACTUAL